However, when comparing the dysphagia scores at baseline and after stent removal/dysphagia recurrence, differences were significant in the biodegradable stent group (2.8 ± 0.42 vs. 2.0 ± 0.82; P = 0.02) and fully covered stent group (2.7 ± 0.48 vs. 1.6 ± 1.26; P = 0.008), but these differences were not observed in the SEPS group (2.8 ± 0.42 vs. 2.4 ± 1.26; P = 0.10).
For example, if subjects were cured with fidaxomicin and received no CAs during the follow-up period, 11.5% experienced recurrence of CDI whereas 23.9% of subjects cured with vancomycin had recurrences (difference, −12.4% [95% CI, −18.0% to −6.57%]; P <.001).
Although inhibiting both FGFR1 and EGFR resulted in delayed recurrence, no difference was observed in initial tumor regression as compared to inhibiting FGFR1 alone.
These signatures were as effective as standard clinical parameters in predicting recurrence/mortality, and when combined, offered some improvement relative to clinical information alone for disease recurrence (median difference in C-values of 0.03, 95% CI of -0.08 to 0.13).
The most striking differences were found in the incidence of the brain as the site of first recurrence, with differences between the groups attenuating over time and after adjusting to clinicopathological factors.
As regards the distant recurrence, no differences were found between the two groups.
Multivariable Cox regression was performed to assess recurrence risk differences between derived subgroups in simultaneous consideration of potential confounding factors.
The availability of targeted systemic therapy has a major impact on risk for local recurrence, and differences in local recurrence rates on the basis of ER, PR and HER-2 are present in patients treated with both mastectomy and BCT.
When the χ test was used to examine the rate of positivity for each of the three tumour markers in the sera of patients with recurrence, significant differences between CYFRA 21-1 and CEA (P<0.0001) and between CYFRA 21-1 and CA 15-3 (P<0.0003) were observed.
We do not wish to draw any conclusions on whether type of surgery influences the risk of recurrence, since differences in personal and clinical characteristics (for example, age, tumor size, and comorbidity) will be different in the groups selected for the two different surgical techniques.
